Brazil takes first concrete step in assessing the economic impact of regulation
This article was originally published in Clinica
The heads of Brazilian healthcare regulatory agency Anvisa are close to receiving a draft framework for the first national assessment of the economic impact of its activities. The group set up to draft the project is expected to report to Anvisa's directorate by the end of this month, according to a statement issued by Anvisa following a conference involving consultants on the project, held on August 11, in Brasilia. This is the first stage in a wider programme to assess the impact of regulation across all industrial sectors, which Anvisa was chosen to pilot (see Clinica No 1318, p 2).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.